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Abstract
Background: Vascular endothelial growth factor (VEGF) has neurotrophic activity which is
mediated by its main agonist receptor, VEGFR2. Dysregulation of VEGF causes motor neurone
degeneration in a mouse model of amyotrophic lateral sclerosis (ALS), and expression of VEGFR2
is reduced in motor neurones and spinal cord of patients with ALS.
Methods: We have screened the promoter region and 4 exonic regions of functional significance
of the VEGFR2 gene in a UK population of patients with ALS, for mutations and polymorphisms
that may affect expression or function of this VEGF receptor.
Results: No mutations were identified in the VEGFR2 gene. We found no association between
polymorphisms in the regulatory regions of the VEGFR2 gene and ALS.
Conclusion: Mechanisms other than genetic variation may downregulate expression or function
of the VEGFR2 receptor in patients with ALS.
Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disorder, in which loss of motor neurones in the
spinal cord, brainstem and cerebral cortex causes progres-
sive paralysis. Ten percent of cases are familial, and one
fifth of these are caused by a mutation in the gene encod-
ing superoxide dismutase (SOD1). In the majority of
familial and sporadic cases of ALS, the cause of selective
loss of motor neurones is unknown, but there is growing
evidence of the importance of dysregulation of vascular
endothelial growth factor (VEGF) as a factor in motor
neurone degeneration.
VEGF is an endothelial cell mitogen essential for angio-
genesis, and upregulated by hypoxia. In 2001, Oosthuyse
et al found that deletion of the hypoxia response element
of the VEGF gene in mice caused motor neurone degener-
ation with clinical and pathological features similar to
ALS [1]. VEGF was subsequently shown to act as a neuro-
trophic factor in vitro and in vivo [1,2]. VEGFR2 (also
known as KDR) is the major agonist receptor of VEGF, and
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has been shown to mediate its neuroprotective effects in
vitro [1]. Neuronal overexpression of VEGFR2 in SOD1
transgenic mice delays the onset of motor impairment,
and prolongs survival [3]. A recent immunohistochemical
study showed that the expression of both VEGF and
VEGFR2 was downregulated on anterior horn cells, and
VEGFR2 immunostaining in the neuropil was decreased
in the spinal cord in patients with ALS, compared to nor-
mal controls [4].
The role of VEGFR2 in the mediation of the neurotrophic
effects of VEGF, and its reduced expression in neural tissue
of ALS patients identify it as an important candidate gene
in ALS. We have sequenced the 5' UTR and promoter
region of the VEGFR2 gene in patients with ALS, to deter-
mine whether the observed downregulation of VEGFR2
expression in ALS patients is related to the segregation of
certain alleles at polymorphic sites within the regulatory
regions of the VEGFR2 in the ALS population. We have
screened the regulatory regions and 4 exons of functional
significance in the VEGFR2 gene for mutations in ALS
patients, which are not present in control populations.
These 4 exons were identified for screening both on the
basis of their functional significance [5], and the presence




Exons 7, 18, 21 and 27 were sequenced in 100 ALS
patients, and exon 7 in 100 unrelated neurologically nor-
mal controls. The regulatory regions were sequenced in
301 ALS patients and 239 unrelated neurologically nor-
mal controls from the north of England. Patients had a
diagnosis of definite or probable ALS by the El Escorial cri-
teria. We included patients with the progressive muscular
atrophy (PMA), primary lateral sclerosis (PLS) and pro-
gressive bulbar palsy (PBP) clinical variants. Approval for
the use of DNA samples was obtained from the local eth-
ics committee.
DNA extraction and PCR reactions
Genomic DNA was extracted from blood, using the
Nucleon BACC3 extraction kit (Tepnel UK), or snap fro-
zen human motor cortex using the Nucleon Soft Tissue Kit
(Tepnel UK). PCR was performed in a 25 μl volume con-
taining 100 ng of genomic DNA, 10 pmol of each primer,
and 12.5 μl of 2× ReddyMix™ PCR Master Mix (ABgene).
5% DMSO was added to the reaction mix to amplify the
promoter region. After an initial denaturing step of 95°C
for 5 mins, samples were amplified in 35 cycles of 95°C
30 s, annealing temperature 30 s, 72°C 45 s, followed by
a final incubation of 72°C for 10 minutes. Primer pairs
were obtained from MWG Biotech. (Table 1 details primer
pairs and annealing temperatures)
Mutation screening and detection of polymorphisms
PCR products of DNA samples were sequenced directly
with an ABI 3730 DNA analyser, using the Big Dye® Termi-
nator Cycle Sequencing Kit, according to manufacturer's
instructions. VEGFR2 sequence was taken from
ENSCAFG00000002079 on the ensembl database [6],
which was used to determine sites of known polymor-
phisms. Numbering of nucleotides is relative to the trans-
lation start site. Polymorphism -57C/T was confirmed
using restriction digest with NlaIV. Reaction conditions
were: 5 μl PCR product, 1 unit of NlaIV (New England
Biolabs), 1×NEB buffer 4, 100 μg/ml BSA in a total vol-
ume 10 μl; incubated at 37°C for 1 hour.
Statistics
Allele frequencies were analysed using Chi-Square test.
Results
All patients and controls were from Caucasian back-
grounds. 58% of patients were male, and the mean age
was 61.8. 8.6% of patients had one of the clinical variants
Table 1: Primers used to amplify regulatory and exonic regions of the VEGFR2 gene, and polymorphisms present.
Polymorphisms Amino acid change SNP reference Forward primer Reverse primer Annealing 
temperature
Promoter -305 C/T n/a Novel GCGACCCGGCATACTTG AGGCGGCCCGGGTCTCCAC 55
-263 C/T Novel
-123 C/G Rs 10027862
-65 C/T Rs 9994560
-57 C/T Novel
-17 A/T Rs 6824124
5' UTR +31 G/A Rs 7667298
Exon 7 +1192 G/A Val to Ile Rs 2305948 CTGGTGTCCCTGTTTTTAGCAT GTATATCAGCACATCTCATCTTTA 50
Exon 18 +2846 T/A Val to Glu Rs 1139776 TAATTAAGCCAGGACAAAGGAGTA CTAGTAGGCCCACATAAGCACA 50
Exon 21 +3157 T/C Val to Ile Rs 13129474 TTCAATTATCTCCATGGTTTACTA TCACTTTTGGGGAGACAGAAT 46
Exon 27 +3931 C/G Pro to Ala Rs 11540507 CACCCTATGTAGCCAAGAAGTC CTACAGATGGGAGGAAGCACAC 53
SNP reference obtained from ensembl database for known polymorphisms; Novel polymorphisms are those identified in this study. Primers are 
listed 5' to 3'
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of ALS (5.6% PMA, 2% PLS and 1% PBP). In the control
population, 56% were male, and the mean age was 56.6.
Exons 7, 18, 21 and 27 of the VEGFR2 gene were screened
for mutations or polymorphisms in 100 ALS patients.
Exon 7 lies within the VEGF binding domain and exons
18 and 21 within the protein kinase domain. The function
of exon 27 is unknown, but it is a region that is highly
conserved across species. No mutations were identified in
the exons or intron/exon boundaries of exons 7, 18, 21 or
27. The previously described polymorphisms in exons 18,
21 and 27 were not present in this population of ALS
patients. The A allele at position +1192 in exon 7 was
present at a frequency of 0.06 in both ALS and control
populations (Table 2), consistent with its published fre-
quency [6].
The VEGFR2 5' UTR and promoter region was sequenced
from -315 to +302 relative to the transcription start site,
which includes the core promoter region of the VEGFR2
gene (Figure 1) [7], in 301 ALS patients and 239 unrelated
neurologically normal controls. Five polymorphisms were
identified in these regulatory regions, of which three were
novel (305 C/T, -263 C/T, and -57 C/T). Previously
described polymorphisms [6] -123C/G and -17A/T were
not seen. There was no difference in frequency of poly-
morphisms -305 C/T, -263 C/T, -65 C/T and +31 A/G in
the ALS population, relative to the control population
(Table 2). The novel polymorphism -57 C/T is located in
a consensus sequence for binding SP1, the major tran-
scriptional regulator of VEGFR2 [8,9], and was found in
one patient and one control case (Figure 2)
Discussion
The VEGF signalling pathway has an important role in the
maintenance of neuronal survival, and dysregulation of
this pathway leads to motor neurone death. A meta-anal-
ysis of pooled European populations demonstrated that
two haplotypes of functional polymorphisms in the 5'
UTR of the VEGF gene conferred a 1.8 fold greater risk of
ALS [2], although in other populations, no association
between VEGF polymorphisms and ALS is seen [2,10,11].
This does not exclude the possibility that dysregulation of
the VEGF signalling pathway plays a role in the pathogen-
esis of ALS in these patients, as genetic factors may also
control response to VEGF [12]. We have previously shown
Diagrammatic representation of the regulatory regions of the VEGFR2 gene from -225 to +127, showing consensus regions for transcription factor bi ding sitesFigure 1
Diagrammatic representation of the regulatory regions of the VEGFR2 gene from -225 to +127, showing consensus regions for 
transcription factor binding sites.
Table 2: Frequencies of polymorphisms in the regulatory regions and exon 7 in ALS and control populations
Polymorphism Allele ALS patients Controls Chi squared
Allele Frequency Allele Frequency
-305 C/T C 262 (0.44) 179 (0.43)
T 340 (0.56) 239 (0.57) 0.838
-263 C/T C 450 (0.75) 303 (0.72)
T 152 (0.25) 115 (0.28) 0.381
-65 C/T C 293 (0.49) 309 (0.50)
T 210 (0.51) 208 (0.50) 0.621
+31 G/A G 325 (0.54) 277 (0.56)
A 232 (0.46) 186 (0.44) 0.641
+1192 G/A G 182 (0.94) 180 (0.94)
A 12 (0.06) 12 (0.06) 0.979
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that expression of VEGFR2 is downregulated in the CNS
of ALS patients [4]. In this study we have addressed the
question of whether sequence variation in the regulatory
regions of the VEGFR2 gene in ALS patients may contrib-
ute to lower expression of this VEGF agonist receptor. We
have sequenced important functional regions of this can-
didate gene, to determine whether sequence variation in
the coding regions could affect function of the receptor,
and therefore responsiveness to VEGF in ALS.
No mutations or differences in polymorphism frequency
were identified in the ALS population, in the regulatory
regions or 4 coding regions of probable functional signif-
icance. These findings do not support the hypothesis that
genetic factors reduce VEGF responsiveness in ALS, via
downregulation of expression or function of VEGFR2.
This study had a power of 89% to detect a relative risk of
1.8 at 0.05 significance level, therefore the lack of associa-
tion between VEGFR2 promoter region polymorphisms
and ALS is unlikely to be due to sample size.
Mechanisms other than genetic factors may reduce
VEGFR2 expression in ALS. In ALS patients without 'at-
risk' VEGF haplotypes, decreased plasma levels of VEGF
were also identified [2]. Similarly, reduced expression of
VEGFR2 may occur secondary to other disease mecha-
nisms, such as gene downregulation due to dysregulation
of transcription factors, which is seen in a mutant SOD1
cell model of ALS [13]. VEGFR2 is a large gene with 30
exons, and although we selected functionally significant
regions of the gene, we have not excluded the possibility
that sequence variation in other exonic regions could dis-
rupt the function of this protein in ALS patients.
Conclusion
There is no evidence from sequencing of the regulatory
regions and 4 functionally significant exonic regions of
the VEGFR2 that genetic variation in this agonist receptor
causes downregulation of VEGF signalling in ALS patients.
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